

Denis Larsimont

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8211346/publications.pdf>

Version: 2024-02-01

58
papers

2,265
citations

257450

24
h-index

233421

45
g-index

59
all docs

59
docs citations

59
times ranked

4160
citing authors

#	ARTICLE	IF	CITATIONS
1	Abstract P1-02-09: Results of a worldwide survey on the currently used histopathological diagnostic criteria for invasive lobular breast cancer (ILC). <i>Cancer Research</i> , 2022, 82, P1-02-09-P1-02-09.	0.9	0
2	Abstract P4-02-02: The association between adiposity and anti-proliferative response to neoadjuvant endocrine therapy with letrozole in post-menopausal patients with estrogen receptor positive breast cancer. <i>Cancer Research</i> , 2022, 82, P4-02-02-P4-02-02.	0.9	0
3	Histopathological growth patterns of liver metastasis: updated consensus guidelines for pattern scoring, perspectives and recent mechanistic insights. <i>British Journal of Cancer</i> , 2022, 127, 988-1013.	6.4	30
4	Transcriptional output, cell-type densities, and normalization in spatial transcriptomics. <i>Journal of Molecular Cell Biology</i> , 2021, 12, 906-908.	3.3	27
5	Inferior epigastric artery lymph nodes: A pathway for systemic dissemination from peritoneal carcinomatosis?. <i>Journal of Surgical Oncology</i> , 2021, 123, 311-314.	1.7	4
6	Absence of residual fluorescence in the surgical bed at near-infrared fluorescence imaging predicts negative margins at final pathology in patients treated with breast-conserving surgery for breast cancer. <i>European Journal of Surgical Oncology</i> , 2021, 47, 269-275.	1.0	19
7	Clinico-metabolic characterization improves the prognostic value of histological growth patterns in patients undergoing surgery for colorectal liver metastases. <i>Journal of Surgical Oncology</i> , 2021, 123, 1773-1783.	1.7	7
8	The genomic landscape of carcinomas with mucinous differentiation. <i>Scientific Reports</i> , 2021, 11, 9478.	3.3	9
9	Circulating Tumor DNA to Interrogate the Safety of Letrozole-Associated Controlled Ovarian Stimulation for Fertility Preservation in Breast Cancer Patients. <i>Frontiers in Oncology</i> , 2021, 11, 686625.	2.8	5
10	Fluorescent Multiplex Immunohistochemistry Coupled With Other State-Of-The-Art Techniques to Systematically Characterize the Tumor Immune Microenvironment. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 673042.	3.5	19
11	Functional Th1-oriented T follicular helper cells that infiltrate human breast cancer promote effective adaptive immunity. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	70
12	Extended time interval between diagnosis and surgery does not improve the outcome in patients operated for resection or ablation of breast cancer liver metastases. <i>European Journal of Surgical Oncology</i> , 2020, 46, 229-234.	1.0	5
13	Infiltrative tumour growth pattern correlates with poor outcome in oesophageal cancer. <i>BMJ Open Gastroenterology</i> , 2020, 7, e000431.	2.7	2
14	Phylogenetic reconstruction of breast cancer reveals two routes of metastatic dissemination associated with distinct clinical outcome. <i>EBioMedicine</i> , 2020, 56, 102793.	6.1	22
15	Digital analysis of distant and cancer-associated mammary adipocytes. <i>Breast</i> , 2020, 54, 179-186.	2.2	5
16	Characterization of Stromal Tumor-infiltrating Lymphocytes and Genomic Alterations in Metastatic Lobular Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 6254-6265.	7.0	22
17	Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells. <i>Nature Communications</i> , 2020, 11, 6335.	12.8	46
18	Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 17.	5.2	106

#	ARTICLE	IF	CITATIONS
19	The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immunology biomarkers in breast cancer clinical trials and daily practice. <i>Journal of Pathology</i> , 2020, 250, 667-684.	4.5	142
20	Association between the histopathological growth patterns of liver metastases and survival after hepatic surgery in breast cancer patients. <i>Npj Breast Cancer</i> , 2020, 6, 64.	5.2	20
21	Systemic Sentinel Lymph Node Detection Using Fluorescence Imaging After Indocyanine Green Intravenous Injection in Colorectal Cancer: Protocol for a Feasibility Study. <i>JMIR Research Protocols</i> , 2020, 9, e17976.	1.0	8
22	Reprogramming of Energy Metabolism: Increased Expression and Roles of Pyruvate Carboxylase in Papillary Thyroid Cancer. <i>Thyroid</i> , 2019, 29, 845-857.	4.5	25
23	Molecular apocrine tumours in EORTC 10994/BIG 1-00 phase III study: pathological response after neoadjuvant chemotherapy and clinical outcomes. <i>British Journal of Cancer</i> , 2019, 120, 913-921.	6.4	11
24	Genomic, Transcriptomic, Epigenetic, and Immune Profiling of Mucinous Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2019, 111, 742-746.	6.3	40
25	BRCA gene mutations do not shape the extent and organization of tumor infiltrating lymphocytes in triple negative breast cancer. <i>Cancer Letters</i> , 2019, 450, 88-97.	7.2	33
26	ESR1 mutations in metastatic lobular breast cancer patients. <i>Npj Breast Cancer</i> , 2019, 5, 9.	5.2	26
27	Comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancer. <i>Breast Cancer Research</i> , 2019, 21, 151.	5.0	30
28	FOXP1 negatively regulates tumor infiltrating lymphocyte migration in human breast cancer. <i>EBioMedicine</i> , 2019, 39, 226-238.	6.1	36
29	Tumor-infiltrating B cells signal functional humoral immune responses in breast cancer. <i>JCI Insight</i> , 2019, 4, .	5.0	182
30	Histological growth pattern as a potential prognostic factor in patients operated for breast cancer liver metastases.. <i>Journal of Clinical Oncology</i> , 2019, 37, e12576-e12576.	1.6	1
31	Histological growth pattern as a potential marker of oligometastatic disease in patients operated for colorectal liver metastases.. <i>Journal of Clinical Oncology</i> , 2019, 37, e15093-e15093.	1.6	0
32	Immune Infiltration in Invasive Lobular Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2018, 110, 768-776.	6.3	76
33	Genomic hotspots but few recurrent fusion genes in breast cancer. <i>Genes Chromosomes and Cancer</i> , 2018, 57, 331-338.	2.8	18
34	Distinctive Desmoplastic 3D Morphology Associated With BRAFV600E in Papillary Thyroid Cancers. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 1102-1111.	3.6	11
35	ICG-fluorescence imaging for detection of peritoneal metastases and residual tumoral scars in locally advanced ovarian cancer: A pilot study. <i>Journal of Surgical Oncology</i> , 2018, 117, 228-235.	1.7	42
36	Antigen Specificity and Clinical Significance of IgG and IgA Autoantibodies Produced in situ by Tumor-Infiltrating B Cells in Breast Cancer. <i>Frontiers in Immunology</i> , 2018, 9, 2660.	4.8	65

#	ARTICLE	IF	CITATIONS
37	Ex vivo indocyanine green fluorescence imaging for the detection of lymph node involvement in advanced-stage ovarian cancer. <i>Journal of Surgical Oncology</i> , 2018, 118, 1163-1169.	1.7	11
38	ICG fluorescence imaging as a new tool for optimization of pathological evaluation in breast cancer tumors after neoadjuvant chemotherapy. <i>PLoS ONE</i> , 2018, 13, e0197857.	2.5	23
39	The impact of breast MRI workup on tumor size assessment and surgical planning in patients with early breast cancer. <i>Breast Journal</i> , 2018, 24, 927-933.	1.0	17
40	Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number aberrations. <i>Nature Communications</i> , 2017, 8, 14944.	12.8	126
41	Reliability of tumor-infiltrating lymphocyte and tertiary lymphoid structure assessment in human breast cancer. <i>Modern Pathology</i> , 2017, 30, 1204-1212.	5.5	81
42	<scp>CDK</scp>4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclib. <i>EMBO Molecular Medicine</i> , 2017, 9, 1052-1066.	6.9	65
43	Tumor-infiltrating lymphocyte composition, organization and PD-1/ PD-L1 expression are linked in breast cancer. <i>Oncolmmunology</i> , 2017, 6, e1257452.	4.6	169
44	Immune Checkpoint Molecules on Tumor-Infiltrating Lymphocytes and Their Association with Tertiary Lymphoid Structures in Human Breast Cancer. <i>Frontiers in Immunology</i> , 2017, 8, 1412.	4.8	80
45	N-Acetylcysteine breaks resistance to trastuzumab caused by MUC4 overexpression in human HER2 positive BC-bearing nude mice monitored by 89Zr-Trastuzumab and 18F-FDG PET imaging. <i>Oncotarget</i> , 2017, 8, 56185-56198.	1.8	11
46	Classical risk factors, but not HPV status, predict survival after chemoradiotherapy in advanced head and neck cancer patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 2185-2196.	2.5	32
47	Ex vivo detection of tumoral lymph nodes of colorectal origin with fluorescence imaging after intraoperative intravenous injection of indocyanine green. <i>Journal of Surgical Oncology</i> , 2016, 114, 348-353.	1.7	26
48	The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence. <i>JAMA Oncology</i> , 2016, 2, 217.	7.1	21
49	Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast Cancer. <i>PLoS ONE</i> , 2016, 11, e0154009.	2.5	27
50	Sentinel Lymph Node Detection by Blue Dye Versus Indocyanine Green Fluorescence Imaging in Colon Cancer. <i>Anticancer Research</i> , 2016, 36, 4853-4858.	1.1	35
51	Uncovering the genomic heterogeneity of multifocal breast cancer. <i>Journal of Pathology</i> , 2015, 236, 457-466.	4.5	72
52	No significant viral transcription detected in whole breast cancer transcriptomes. <i>BMC Cancer</i> , 2015, 15, 147.	2.6	15
53	Principles Governing A-to-I RNA Editing in the Breast Cancer Transcriptome. <i>Cell Reports</i> , 2015, 13, 277-289.	6.4	179
54	Feasibility study of cationic liposome-encapsulated paclitaxel in combination with paclitaxel followed by FEC as induction therapy in HER2-negative breast cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, e12008-e12008.	1.6	0

#	ARTICLE	IF	CITATIONS
55	Use of mutational profiling of metastatic ER+/HER2- breast cancers and the coexistence of KRAS, MET, BRAF, and FGFR3 with PIK3CA mutations.. Journal of Clinical Oncology, 2013, 31, 11003-11003.	1.6	0
56	HER-2/neu evaluation by immunohistochemistry and fluorescence in situ hybridization in breast cancer: implications for daily laboratory practice. Anticancer Research, 2002, 22, 2485-90.	1.1	8
57	Sensitivity of HER-2/neu Antibodies in Archival Tissue Samples of Invasive Breast Carcinomas. American Journal of Clinical Pathology, 2000, 113, 675-682.	0.7	84
58	Establishment and characterization of three new breast-cancer cell lines. , 1998, 76, 677-683.		19